Drug Profile


Alternative Names: Beta-IFN/PCB; Phycocyanobilin/interferon-beta

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 01 Dec 2014 Interferon-beta/phycocyanobilin is available for licensing as of 01 Dec 2014.
  • 01 Dec 2014 Preclinical trials in Multiple sclerosis in Cuba (unspecified route) prior to December 2014 (CIGB presentation, 2014-2015)
  • 10 Jan 2013 CIGB has patent protection for Interferon-beta/phycocyanobilin in world
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top